Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis
Xianjing Chu(Central South University), Rongrong Zhou(Central South University), Wentao Tian(Central South University), Jiaoyang Ning(Central South University)
Cited by 13
Related Papers
Cancer stem cells: advances in knowledge and implications for cancer therapy
|Signal Transduction and Targeted Therapy|2024|452
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
|Molecular Cancer|2023|194
Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments
|Frontiers in Cell and Developmental Biology|2021|78
The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis
|Frontiers in Immunology|2022|55
<p>Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma</p>
|Cancer Management and Research|2019|33